Shares of Kadmon Holdings (KDMN) have risen by 29% since my 2017 ASH update highlighted mid-stage data for ROCK2 inhibitor KD025 in patients with chronic graft-versus-host disease (cGVHD). Shares have risen by 88% since my Buy recommendation in July, where I noted that completion of the phase 3 program was in sight and additional assets offered optionality.
After positive pivotal results were reported in November followed by a successful financing, this platform technology play appears even more derisked. At this point, my objective is to determine what further upside investors can expect